Towards an evaluation of alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients with hematological scales

Table 1 Clinical characteristics of study participants

Parameter	ALC (n = 142)	NAFLD (n = 92)	Controls (n = 68)	Together (n = 302)
Sex (F/M)	36/106	33/59	36/32	105/197
Age (yr), (mean ± SD; median; min-max)	54 ± 12; 55; 31-84	60 ± 15; 61; 22-90	46 ± 16; 45; 20-85	54 ± 15; 55; 20-90
BMI (kg/m2) (mean ± SD; median; min-max)	25.89 ± 9.31; 25.91; 16.7-36.71	29.49 ± 4.9; 28.7; 16.26-43.01	21.95 ± 2.62; 22.45; 16.18-24.86	-
DM type 2	0/142	22/92	-	-
AH	32/142	46/92	-	-

F: Female; M: Male; SD: Standard deviation; min: Minimum; max: Maximum; BMI: Body mass index; DM: Diabetes mellitus; AH: Arterial hypertension.

Table 2 Results of used scores in research group

Score	ALC					NAFLD
	Mean	SD	Median	Min	Max	Mean	SD	Median	Min	Max
MELD	17	8	16	6	45	-	-	-	-	-
BARD	-	-	-	-	-	2	1	2	0	4
NAFLD fibrosis score	-	-	-	-	-	-1.36	1.5	-1.16	-5.83	1.74

SD: Standard deviation; Min: Minimum; Max: Maximum; MELD: Model for end-stage liver disease; NAFLD: Nonalcoholic fatty liver disease.

Table 3 Results of hematological indices and serological (indirect and indirect) markers of liver fibrosis in examined patients

Parameter (reference range)	ALC					NAFLD					Controls
	Mean	SD	Median	Min	Max	Mean	SD	Median	Min	Max	Mean	SD	Median	Min	Max
NLR	6.3	6.99	4.09d	0.53	49.84	3.4	2.84	2.63d	0.17	17.33	1.97	1.09	1.77	0.81	6.2
PLR	120.85	87.18	99.49d	0.7	435.82	182.78	128.93	139.55	8.94	742.86	154.88	64.92	141.59	56.9	327.27
MPR	0.15	0.29	0.09d	0.02	3.28	0.04	0.02	0.03	0.01	0.1	0.03	0.01	0.03	0.02	0.06
AAR	2.19	1.16	1.89d	0.18	7.57	1.03	0.55	0.91a	0.23	3.1	1.15	0.43	1.1	0.43	2.86
APRI	4.35	7.02	2.43d	0.15	68.38	0.81	1.04	0.48d	0.13	7.67	0.25	0.13	0.23	0.11	0.86
FIB-4	11.67	25.46	6.34d	0.69	287.59	1.92	1.63	1.57d	0.23	11.58	0.85	0.54	0.71	0.28	3.27
GPR	15.73	28.54	6.65d	0.18	188.71	2.76	5.57	0.54d	0.13	35.41	0.25	0.1	0.24	0.06	0.63
PICP (ng/mL)	63.32	31.53	60.53	6.15	161.12	52.14	27.56	46.08	10.10	147.27	58.26	37.39	44.18	0	202.89
PIIINP (ng/mL)	9.28	4.33	8.4b	2.43	28.65	11.41	3.99	11.00	2.18	25.35	11.07	5.61	10.25	4.35	43.63
PDGF-AB (pg/mL)	18280.47	8061.06	17343.71c	1925.68	42823.84	26858.68	7335.09	26682.83	10821.02	49808.07	23579.28	10068.8	25623.2	1638.2	47758.7
TGF-α (pg/mL)	24	45.33	13.77d	0.872	507.09	17.89	19.18	12.09d	1.39	142.63	28.44	17.21	24.59	1.31	93.55
Laminin (ng/mL)	976.34	705.29	832.06a	101.933	3301.00	48	230.24	375.23d	72.87	1335.92	718.24	386.1	663.27	140.88	1813.88

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

^dP < 0.0001. ALC: Alcoholic liver cirrhosis; NAFLD: Nonalcoholic fatty liver disease; SD: Standard deviation; Min: Minimum; Max: Maximum; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; MPR: Mean platelet volume-to-platelet-ratio; AAR: Aspartate transaminase to alkaline transaminase ratio; APRI: Aspartate transaminase to platelet ratio index; FIB-4: Fibrosis-4; GPR: Gamma-glutamyl transpeptidase to platelet ratio; PICP: Procollagen I carboxyterminal propeptide; PIIINP: Procollagen III aminoterminal propeptide; PDGF-AB: Platelet-derived growth factor AB; TGF-α: Transforming growth factor-α.

Table 4 Correlations between examined parameters in examined alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients

Pair	R Spearman	P value
ALC
MPR and APRI	0.691	c
MPR and FIB-4	0.776	c
NLR and AAR	0.173	a
NLR and GPR	0.183	a
PLR and APRI	-0.535	c
PLR and FIB-4	-0.557	c
MPR and MELD	0.343	d
NLR and MELD	0.379	d
PLR and MELD	-0.235	b
NLR and PIIINP	-0.183	a
MPR and PDGF-AB	-0.366	c
PLR and PDGF-AB	0.272	b
NAFLD
MPR and APRI	0.557	d
MPR and FIB-4	0.603	d
MPR and GPR	0.303	b
MPR and NFS	0.587	d

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

^dP < 0.0001. ALC: Alcoholic liver cirrhosis; NAFLD: Nonalcoholic fatty liver disease; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; MPR: Mean platelet volume-to-platelet-ratio; AAR: Aspartate transaminase to alkaline transaminase ratio; APRI: Aspartate transaminase to platelet ratio index; FIB-4: Fibrosis-4; GPR: Gamma-glutamyl transpeptidase to platelet ratio; PICP: Procollagen I carboxyterminal propeptide; PIIINP: Procollagen III aminoterminal propeptide; PDGF-AB: Platelet-derived growth factor AB.

Table 5 Diagnostic accuracy of hematological indices in examined alcoholic liver cirrhosis and nonalcoholic fatty liver disease patients

Parameter	ALC						NAFLD
	Diagnostic accuracy						Diagnostic accuracy
	AUC	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	P value	AUC	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	P value
NLR	0.821	78	80	89	63	d	0.725	72	71	77	65	d
PLR	0.675	35	97	96	42	d	0.528	88	18	59	52	-
MPR	0.929	85	94	97	75	d	0.547	39	78	71	49	-

^dP < 0.0001. ALC: Alcoholic liver cirrhosis; NAFLD: Nonalcoholic fatty liver disease; AUC: Area under the curve; PPV: Positive predictive value; NPV: Negative predictive value.